Journal
PHARMACEUTICALS
Volume 14, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/ph14080819
Keywords
antifibrotic agents; COVID-19; interstitial lung disease; IPF; progressive fibrosing ILD; UIP; pharmacological interactions
Categories
Ask authors/readers for more resources
The discovery of antifibrotic agents has advanced the therapeutic management of idiopathic pulmonary fibrosis (IPF). Nintedanib and pirfenidone are now the foundation of IPF therapy, with potential to enhance treatment efficacy when used together. However, limited information exists on drug-drug interactions between these two medications, especially in polymedicated patients.
The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug-drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available